Systematic Review of Enalapril-folic Acid Tablet in Treatment of H-type Hypertension

OBJECTIVE To evaluate the clinical efficacy and safety of enalapril-folic acid in the treatment of H-type hypertension. METHODS Retrieved from CNKI, VIP, Wanfang database, PubMed, Medline and EMBase, RCTs about Enalapril-folie acid treatment of H-type hypertension were collected and evaluated by Cochrane systematic review. Meta-analysis was carried out by using RevMan 5.0 software. RESULTS The 17 studies were included, involving 2 323 patients. Meta-analysis showed that there was statistical significant between enalapril-folic acid and enalapril on SBP(WMD=-6.73, 95%CI: -10.13- -3.39, Z=3.93, P<0.05), DBP(WMD=-6.76, 95%CI: -10.23- -2.51, Z=5.96, P<0.05) and Hcy(WMD=-4.18, 95%CI: -6.58- -3.03, Z=5.32, P<0.05). The incidence of cardiovascular events in both group had significant difference (OR=0.28, 95%CI: 0.18-0.43, Z=5.96, P<0.05) and the common adverse reactions had no significant difference. CONCLUSION Enalapril-folic acid is more effective and safety than enalapril for treatment of H-type hypertension.